Skip to content
Bored Studies
RecruitingPhase 2

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

Actio Biosciences, Inc. · NCT07600736

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 1 mo–21 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
61
US sites recruiting
1
Study start
May 18, 2026
Record last updated
October 15, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

Being studied: ABS-1230; Placebo

Conditions: KCNT1-Related Epilepsy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Aged 1 month to \<22 years
  • Clinician-confirmed diagnosis of KCNT1-related epilepsy
  • Has an average of at least 4 countable motor seizures per week
  • Is taking no more than 6 antiseizure medications (ASM) and is able to keep stable doses of ASMs for the duration of Part 1 or Part 2

Exclusion Criteria

  • Is currently taking phenytoin, carbamazepine, stiripentol, or quinidine
  • Has a medical condition that, in the opinion of the investigator, would limit the participant's ability to participate in the study or might compromise participant safety or interfere with evaluation of the study drug.

Recruiting US locations

  • Northeast Regional Epilepsy Group

    Hackensack, NJ 07601

    Site contact: Hardik Rana · 551-497-5000 · HRana@epilepsygroup.com

Study contacts (from the official record)

  • Medical Director Actio Biosciences, Inc. · +1 (858) 682-4042 · info@actiobiosciences.com
All neurology studies in New Jersey →
A Study to Investigate the Safety, Tolerability, Pharmacokinetics,… (NCT07600736) | Bored Studies